ArticleFrontiers in psychiatry2026
Modified electroconvulsive therapy for treatment-resistant self-injurious behavior in autism spectrum disorder with severe intellectual disability: a case report.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Treatment options for severe self-injurious behavior (SIB) in autism spectrum disorder (ASD) with comorbid intellectual disability (ID) are limited. Case presentation: A 24-year-old man with ASD and severe ID presented with treatment-refractory SIB (an 11-year history; baseline frequency of 5-6 hand-biting episodes per day during pre-modified electroconvulsive therapy (MECT) hospitalization observation), despite multiple pharmacotherapy trials. On Day 27, baseline assessments and pre-MECT demonstrated a Violence Risk Assessment Scale (VRAS) score of 18, a Brief Psychiatric Rating Scale (BPRS) score of 74, an Activities of Daily Living (ADL) score of 46, and 4-5 h of nocturnal sleep each night. After 12 sessions of MECT administered over 7 weeks, the primary outcome, that is, SIB frequency, completely resolved (no hand-biting episodes each day). Additionally, secondary outcome measures showed marked improvement, including a VRAS score of 7 (a 61.1% reduction), a BPRS score of 47 (a 36.5% reduction), an ADL score of 34 (a 26.1% improvement in functional independence), and 5-6 h of nocturnal sleep each night. At 30 days post-MECT (Day 106, during continued hospitalization), therapeutic gains were sustained and further enhanced: the VRAS score persisted at 7, the BPRS score decreased to 35 (a 52.7% reduction from baseline), and the ADL score improved to 30 (a 34.8% improvement in functional independence from baseline), with complete resolution of SIB (self-directed harmful acts) and aggressive behavior (other-directed harmful acts). The patient scored zero on the VRAS. No serious adverse events were observed during hospitalization. Conclusion: Based on controlled nursing frequency counts, mental assessment scales, and photographic wound records, this case provides preliminary observational evidence that MECT may reduce treatment-refractory SIB in patients with ASD and severe ID. Further controlled studies using standardized SIB outcome measures are warranted, given the lack of validated SIB-specific instruments and the limitations inherent to a single-case design.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.